These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

829 related articles for article (PubMed ID: 21062104)

  • 41. Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.
    Chaiamnuay S; Allison JJ; Curtis JR
    Am J Health Syst Pharm; 2006 Oct; 63(19):1837-51. PubMed ID: 16990630
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis.
    Lanas A; Garcia-Tell G; Armada B; Oteo-Alvaro A
    BMC Med; 2011 Apr; 9():38. PubMed ID: 21489310
    [TBL] [Abstract][Full Text] [Related]  

  • 43. COX-2 selective inhibitors in the treatment of osteoarthritis.
    Laine L; White WB; Rostom A; Hochberg M
    Semin Arthritis Rheum; 2008 Dec; 38(3):165-87. PubMed ID: 18177922
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Co-prescription of gastroprotective agents in patients taking non-selective NSAIDs or COX-2 selective inhibitors: analysis of prescriptions.
    Pasina L; Nobili A; Tettamanti M; Riva E; Lucca U; Piccinelli R; Defendi L; Perego L; Lucifora S; Bulla C
    Int J Clin Pharmacol Ther; 2010 Nov; 48(11):735-43. PubMed ID: 20979932
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy.
    Dubois RW; Melmed GY; Henning JM; Laine L
    Aliment Pharmacol Ther; 2004 Jan; 19(2):197-208. PubMed ID: 14723611
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
    Gertz BJ; Krupa D; Bolognese JA; Sperling RS; Reicin A
    Curr Med Res Opin; 2002; 18(2):82-91. PubMed ID: 12017215
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacoeconomic modeling of prior-authorization intervention for COX-2 specific inhibitors in a 3-tier copay plan.
    Stacy J; Shaw E; Arledge MD; Howell-Smith D
    J Manag Care Pharm; 2003; 9(4):327-34. PubMed ID: 14613451
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
    Targownik LE; Metge CJ; Leung S; Chateau DG
    Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
    Hur C; Chan AT; Tramontano AC; Gazelle GS
    Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Selective COX-2 inhibitors: a health economic perspective.
    Schwappach DL; Koeck CM
    Wien Med Wochenschr; 2003; 153(5-6):116-22. PubMed ID: 12705064
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity.
    Yuan JQ; Tsoi KK; Yang M; Wang JY; Threapleton DE; Yang ZY; Zou B; Mao C; Tang JL; Chan FK
    Aliment Pharmacol Ther; 2016 Jun; 43(12):1262-75. PubMed ID: 27121479
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review.
    Hooper L; Brown TJ; Elliott R; Payne K; Roberts C; Symmons D
    BMJ; 2004 Oct; 329(7472):948. PubMed ID: 15475342
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-utility analysis and economic burden of knee osteoarthritis treatment: the analysis from the real clinical practice.
    Turajane T; Chaweevanakorn U; Sungkhun P; Larbphiboonpong V; Wongbunnak R
    J Med Assoc Thai; 2012 Oct; 95 Suppl 10():S98-104. PubMed ID: 23451446
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The rate of prescribing gastrointestinal prophylaxis with either a proton pump inhibitor or an H2-receptor antagonist in Nova Scotia seniors starting nonsteroidal anti-inflammatory drug therapy.
    Superceanu B; Veldhuyzen van Zanten S; Skedgel C; Shepherd M; Sketris I
    Can J Gastroenterol; 2010 Aug; 24(8):481-8. PubMed ID: 20711527
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.
    Wielage RC; Bansal M; Andrews JS; Klein RW; Happich M
    Appl Health Econ Health Policy; 2013 Jun; 11(3):219-36. PubMed ID: 23616247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. NSAID induced gastrointestinal damage and designing GI-sparing NSAIDs.
    García-Rayado G; Navarro M; Lanas A
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):1031-1043. PubMed ID: 30139288
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors.
    Scheiman JM; Yeomans ND; Talley NJ; Vakil N; Chan FK; Tulassay Z; Rainoldi JL; Szczepanski L; Ung KA; Kleczkowski D; Ahlbom H; Naesdal J; Hawkey C
    Am J Gastroenterol; 2006 Apr; 101(4):701-10. PubMed ID: 16494585
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The NSAID dilemma: managing osteoarthritis in high-risk patients.
    Roth SH; Anderson S
    Phys Sportsmed; 2011 Sep; 39(3):62-74. PubMed ID: 22030942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.